Espa?ol
PDFs by language
Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Call us at 1-800-227-2345
Available any time of day or night
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Better understanding of the biology of cancer cells has led to the development of biologic agents that mimic some of the natural signals that the body uses to control cell growth. Clinical trials have shown that this cancer treatment, called biological response modifier (BRM) therapy, biologic therapy, biotherapy, or immunotherapy, is effective for many types of cancer.
Some of these biologic agents, which occur naturally in the body, can now be made in the lab. Examples are interferons, interleukins, and other cytokines. These agents are given to patients to imitate or influence the natural immune response. They do this either by directly altering the cancer cell growth or by acting indirectly to help healthy cells control the cancer.
One of the most exciting applications of biologic therapy has come from identifying certain tumor targets, called antigens, and aiming an antibody at these targets. This method was first used to find tumors and diagnose cancer and more recently has been used to destroy cancer cells. Using technology that was first developed during the 1970s, scientists can mass-produce monoclonal antibodies that are specifically targeted to chemical components of cancer cells. Refinements to these methods, using recombinant DNA technology, have improved the effectiveness and decreased the side effects of these treatments. The first therapeutic monoclonal antibodies, rituximab (Rituxan) and trastuzumab (Herceptin) were approved during the late 1990s to treat lymphoma and breast cancer, respectively. Monoclonal antibodies now are routinely used to treat certain cancers, and many more are being studied.
Scientists are also studying vaccines that boost the body’s immune response to cancer cells. In 2010, the FDA approved sipuleucel-T (Provenge), a cancer vaccine for metastatic hormone-refractory prostate cancer (prostate cancer that has spread and is no longer responding to hormone treatment). Unlike a preventive vaccine, which is given to prevent disease, Provenge boosts the immune system’s ability to attack cancer cells in the body. This treatment has been shown to help certain men with prostate cancer live longer, though it does not cure the disease. It represents an important step forward in cancer treatment.
Drugs aimed at specific immune checkpoints are being developed to help the immune system better kill cancer cells.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
American Society of Clinical Oncology. Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention and Screening. Accessed at www.cancer.net/patient/ASCO%20Resources/Research%20and%20Meetings/CCA_2009.pdf on June 8, 2012.
American Society of Clinical Oncology. Clinical Cancer Advances 2010: ASCO’s Annual Report on Progress Against Cancer. Accessed at www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA_2010.pdf on June 8, 2012.
American Society of Clinical Oncology. Clinical Cancer Advances 2011: ASCO’s Annual Report on Progress Against Cancer. Accessed at www.cancer.net/patient/Publications%20and%20Resources/Clinical%20Cancer%20Advances/CCA_2011.pdf on June 8, 2012.
American Society of Clinical Oncology. Progress & Timeline. Accessed at www.cancerprogress.net/timeline/major-milestones-against-cancer on June 12, 2014.
CureToday. Timeline: Milestones in Cancer Treatment. Accessed at www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article_id/631 on June 7, 2012.
Devita VT Jr, Rosenberg SA. Two Hundred Years of Cancer Research. N Engl J Med. 2012;366(23):2207-2214.
Hajdu SI, Darvishian F. A Note From History: Landmarks in History of Cancer, Part 5. Cancer. 2013;119(8):1450-1466.
Hajdu SI, Vadmal M. A Note From History: Landmarks in History of Cancer, Part 6. Cancer. 2013;119(23):4058-4082.
Last Revised: June 12, 2014
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.
If this was helpful, donate to help fund patient support services, research, and cancer content updates.